Medtronic shares rallied in early trading, jumping 5.3% to $82.05, after the company released fiscal fourth-quarter FY2026 results that exceeded Wall Street expectations on both revenue and earnings. Management said the company achieved its strongest annual top-line growth in 10 years.
Quarterly and annual results
For the quarter, Medtronic reported revenue of $9.8 billion, up 9.9% year-over-year and 6.6% on an organic basis. Non-GAAP diluted earnings per share were $1.55, narrowly surpassing the analyst consensus of $1.54. For the full fiscal year, reported revenue totaled $36.4 billion, an increase of 8.4% as reported.
Chief Executive Geoff Martha framed the results as a milestone for the company, saying, "Our performance reflects the strongest annual top-line growth Medtronic has delivered in 10 years, powered by disciplined execution across our portfolio and continued operational rigor."
Business highlights
A major contributor to the quarter's outperformance was Cardiac Ablation Solutions, which saw global revenue growth of 78%, including 124% growth in the United States. The unit also gained an additional eight points of U.S. market share, according to the company’s reporting.
Beyond product performance, Medtronic’s board approved a quarterly dividend increase to $0.72 per share, marking the company’s 49th consecutive annual dividend raise. That dividend action was one of several factors that supported investor optimism.
Analyst response and market context
Following the results, BTIG upgraded its rating on the stock from Neutral to Buy and set a $90 price target. Analyst Sean Lavin commented, "MDT has demonstrated consistent MSD organic growth the past several quarters, and the trajectory is improving."
The broader market backdrop was mixed on the day: the Dow Jones rose 1.37%, the S&P 500 was essentially flat and the NASDAQ edged down slightly. The Healthcare Services & Equipment sector advanced modestly, but Medtronic’s single-stock move outpaced its peers.
Outlook and strategic moves
Management provided FY2027 organic revenue growth guidance in a range of 6.75% to 7.25%. The company also pointed to a pipeline of strategic investments that reinforced investor confidence, including the pending approximately $650 million acquisition of SPR Therapeutics and new stakes in cardiac catheter technology companies.
After the results, the stock traded well above its 52-week low of $73.31 and moved toward levels seen earlier in the year, though it remains below its 52-week high of $106.33.
Takeaway
Investors reacted to a combination of an earnings beat, record annual revenue growth, an increased dividend and constructive forward guidance. Those elements together helped push the stock higher during morning trading, reflecting renewed conviction in the company's near-term growth trajectory.